LIDDS AB (publ) (STO:LIDDS)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0100
-0.0030 (-23.08%)
Jan 21, 2026, 1:00 PM CET
-93.29%
Market Cap1.77M
Revenue (ttm)n/a
Net Income (ttm)-5.58M
Shares Out136.46M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume437,000
Average Volume319,012
Open0.0100
Previous Close0.0130
Day's Range0.0100 - 0.0100
52-Week Range0.0100 - 0.2300
Beta-0.03
RSI34.20
Earnings DateFeb 19, 2026

About LIDDS AB

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIDDS
Full Company Profile

Financial Performance

Financial Statements